attention deficiency hyperactivity disorder. Disturbance of activity and attention
Conditions
Interventions
Intervention 1: Intervention group: Duloxetine 1/4 capsule in the first week, 1/2 capsule in second week, 3/4 capsule in third week and 1 capsule in fourth week. Intervention 2: Control group: accordi
if the weight of patient is more than 30 kg, 3 capsule will be daily prescribed for the third week (1 capsule in the morning and 1 capsule at noon and 1 capsule in the afternoon).
Treatment - Drugs
Intervention group: Duloxetine 1/4 capsule in the first week, 1/2 capsule in second week, 3/4 capsule in third week and 1 capsule in fourth week
Control group: according to Ritalin dosage 0.4-1.3 mg/kg, Ritalin 1 capsule for the first week (1/2 in the morning and 1/2 at noon), 2 capsule for the second week (1 capsule in the morning and 1 capsu
if the weight of patient is more than 30 kg, 3 capsule will be daily prescribed for the third week (1 capsule in the morning and 1 capsule at noon and 1 capsule in the afternoon)
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
11 Years to 18 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: diagnostic criteria based on DSM IV for children with ADHD, age range 11-18, no consumption of any effective psychological drugs in past two week Exclusion criteria: mental retardation, any other psychological disorders except for ODD, history of allergy to Duloxetine, serious medical conditions such as heart disease, uncontrolled convulsive disorder, systolic pressure upper than 125 mmhg or resting pulse less than 60 or more than 115 bit/m
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Attention deficiency hyperactivity disorder. Timepoint: Baseline, 2, 4, 6, 8 weeks after treatment. Method of measurement: CANERS test for parents (summerized and edited format) and ADHD rating scale for parents and teacher. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drugs side effects. Timepoint: Baseline, 2,4,6,8 weeks after treatment. Method of measurement: side effect questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRozita Jalilian
Psychiatry research center, Tehran University of Medical Sciences
Outcome results
None listed